There are currently 28 active clinical trials seeking participants for Psoriatic Arthritis research studies. The states with the highest number of trials for Psoriatic Arthritis participants are Florida, Texas, California and Ontario.
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
NCT05590247
Recruiting
Our study aims to determine whether intermittent fasting (IMF) is a valid method to improve psoriasis and psoriatic arthritis (PsA) disease severity and quality of life. Patients within OSU Dermatology with psoriasis and/or psoriatic arthritis will be enrolled in a dietary intervention for a 24-week period. A prospective, single-blind parallel group randomized control trial will include an IMF dietary intervention group and a standard routine diet group for a duration of 24 weeks. After the init... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Psoriasis, Psoriatic Arthritis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: AARR- Chandler AZ, Chandler, Arizona +206 locations
Conditions: Psoriatic Arthritis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Pa0016 50662, Gilbert, Arizona +101 locations
Conditions: Psoriatic Arthritis
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Mesa, Arizona +122 locations
Conditions: Psoriatic Arthritis
Register for Updates
Psoriatic Arthritis D2P Screening
NCT04110522
Recruiting
The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously developed screening questionnaires were intended for use in the setting of a doctor's office to assist providers with referral decisions. However, these screening questionnaires are infrequently used in routine practice because of limitations with time and resources. The study will aim to develop a practical scr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Psoriatic Arthritis
Register for Updates
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
NCT06506916
Recruiting
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Ps0039 50140, Birmingham, Alabama +15 locations
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Register for Updates
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People with Inflammatory Arthritis
NCT06555562
Recruiting
This study is designed to investigate whether non-invasive ultrasound (US) that is optimized for stimulation and can elicit an anti-inflammatory response in people with Inflammatory Arthritis as compared to a sham intervention. The primary endpoint is the change in pro-inflammatory cytokines in blood drawn before and after US. Each participant receives 4 experimental US sessions, one of which is randomly assigned to be placebo.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/10/2025
Locations: Tekton Research, Austin, Texas +1 locations
Conditions: Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Register for Updates
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
NCT05631223
Recruiting
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/07/2025
Locations: University Of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Psoriatic Arthritis
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Sunpharma site no 50, Dothan, Alabama +92 locations
Conditions: Psoriatic Arthritis
Register for Updates
Rheumatology Patient Registry and Biorepository
NCT04402086
Recruiting
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/03/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Register for Updates
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
NCT06588296
Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/26/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix West, Avondale, Arizona +88 locations
Conditions: Psoriatic Arthritis, Obesity
Register for Updates